Welcome to our dedicated page for Charles Riv Labs Intl SEC filings (Ticker: CRL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Charles River Laboratories International, Inc. filings document the company’s operating results, material events, governance matters, and capital-structure disclosures as a New York Stock Exchange-listed issuer with common stock trading under CRL. Form 8-K reports cover quarterly and annual financial results, guidance, share repurchase activity, completed portfolio changes, conference disclosures, and executive appointment and compensation matters.
Proxy materials describe shareholder voting matters, board elections, executive compensation, equity incentive plans, and auditor ratification. The filing record also reflects disclosure categories tied to the company’s drug discovery and development services, including segment performance for Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions, along with forward-looking risk language and compliance matters.
Charles River Laboratories International Chief Executive Officer Birgit Girshick reported equity compensation and related tax withholding transactions. On May 29, 2026, she received a grant of 9,961 shares of common stock at $180.71 per share. On May 30–31, 2026, a total of 1,582 shares were disposed of as tax-withholding transactions at the same price. After these transactions, she directly owned 39,399 shares and indirectly held 40,417 shares through a revocable trust. A footnote states that unvested restricted stock units vest annually on May 29, 2027, 2028, 2029, and 2030.
Charles River Laboratories International director James C. Foster reported a set of equity holdings and one tax-related share disposition in company common stock. The filing shows 1,596 shares of common stock were disposed of at $180.71 per share as a tax-withholding disposition, meaning shares were delivered to cover tax obligations rather than sold in the open market.
After this transaction, Foster directly holds 279,957 shares of common stock. The filing also lists several indirect holdings, including shares held by a spouse, by trusts, and by 2024 and 2025 GRAT vehicles. Overall, the activity appears routine and primarily administrative, focused on updating ownership records and satisfying tax requirements tied to equity compensation.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. executive Victoria L. Creamer, EVP & Chief People Officer, received a grant of 5,135 shares of common stock at $180.71 per share. To cover tax liabilities, 810 shares were disposed of through tax-withholding transactions over two days. Following these compensation-related entries, she directly holds 30,051 common shares.
Charles River Laboratories International, Inc. executive Shannon M. Parisotto reported routine equity compensation activity and related tax withholding. On May 29, 2026, she received a grant of 4,361 shares of Common Stock at $180.71 per share as a compensation award. A footnote states that the underlying unvested restricted stock units vest annually on May 29, 2027, 2028, 2029, and 2030.
To cover tax obligations, a total of 721 shares of Common Stock were disposed of through tax-withholding transactions on May 30 and May 31, 2026, each at $180.71 per share. Following these transactions, she directly holds 11,382 shares of Common Stock. As of May 29, 2026, she also has indirect holdings of 28,510 shares through Karpathos Investments LLC and 8,151 shares held by a trust.
Charles River Laboratories International EVP & Chief People Officer Victoria L. Creamer reported routine share dispositions related to tax withholding. On May 26 and 27, a total of 346 shares of common stock were withheld at prices of $160.30 and $156.73 per share. After these transactions, she directly holds 25,726 shares of common stock.
Charles River Laboratories executive Shannon M. Parisotto reported routine share dispositions tied to compensation and estate planning, not open‑market trading. On May 26 and 27, 2026, 273 shares of common stock were withheld at prices of $160.30 and $156.73 per share to cover tax obligations, leaving 7,742 shares held directly.
On February 6, 2026, 7,169 shares were transferred as a bona fide gift from Parisotto to a revocable trust controlled by her, and are now reported as indirectly owned. Separate from the trust, she also reports indirect ownership of 28,510 shares through Karpathos Investments LLC.
Charles River Laboratories International executive Mark Mintz reported small tax-related share dispositions. On May 26, 2026, 64 shares of Common Stock were withheld at $160.30 per share to cover tax obligations. On May 27, 2026, an additional 47 shares were withheld at $156.73 per share. These transactions were coded as tax-withholding dispositions, not open-market sales, and Mintz now directly holds 7,381 shares of Common Stock.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Chief Executive Officer Birgit Girshick reported routine share movements related mainly to taxes. On May 26 and 27, 2026, she had tax-withholding dispositions totaling 618 shares of common stock, with 376 shares at $160.30 and 242 shares at $156.73.
After these dispositions, she held 31,020 shares directly. A separate holding line shows an additional 40,417 common shares held indirectly through a revocable trust as of May 26, 2026. The filing reflects tax and ownership mechanics rather than open-market buying or selling.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. senior vice president of finance and chief accounting officer Michael Gunnar Knell reported two small tax-related share dispositions. On May 26, 2026, 50 shares of common stock were delivered at $160.30 per share, and on May 27, 2026, 37 shares were delivered at $156.73 per share. Both transactions are classified as tax-withholding dispositions to pay an exercise price or tax liability, rather than open-market sales. Following these transactions, Knell directly holds 14,515 shares of common stock.
Charles River Laboratories International EVP Joseph W. LaPlume reported routine tax-related share dispositions in company stock. On May 27, 185 shares of common stock were surrendered at $156.73 per share, and on May 26, 243 shares were surrendered at $160.30 per share.
Both transactions are coded as tax-withholding dispositions, meaning shares were delivered to cover exercise price or tax liabilities rather than sold in open-market trades. After these events, LaPlume directly holds 27,020 shares of Charles River Laboratories common stock.